Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer
AstraZeneca's� Imfinzi �(durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults